Be the first to like this.

2 comment(s). Last comment by ahbah 2021-06-25 13:23

Posted by MuttsInvestor > 2021-06-25 13:17 | Report Abuse

"" A study by researchers from the University of Texas together with Pfizer and BioNtech and published this month by Nature journal found that antibodies elicited by the vaccine were still able to neutralize all tested variants, including Delta, albeit at reduced strength."""
In another Words....... Reduced Efficacy.
HEADLINE is TOTALLY MISLEADING !!! ( As expected from PFIZER !! )

ahbah

6,064 posts

Posted by ahbah > 2021-06-25 13:23 | Report Abuse

Indonesia’s now in the middle of its most severe wave of the COVID-19 pandemic.

Now thanks in part to a wealthy entrepreneur presently serving as the Minister for State Owned Enterprises (SOE), the country’s national drug regulator authorized the use of ivermectin on an off-label basis targeting COVID-19.

In 2020, the Indonesian government brought in a wealthy, dynamic, and aggressive businessman to shake up and turn around state-owned enterprises known as “SOE.” Now they’ve turned Erick Thohir loose on COVID-19, and there’s nothing but business.

A pragmatic yet big thinker, the new SOE Minister of the Food and Drug Supervisory Agency, known for the acronym BPOM, issued a distribution permit for ivermectin, meaning the regulatory body for this Southeast Asian nation of 270 million, the worlds’ fourth most populous nation, has authorized the use of the generic, low-cost drug as a therapeutic for COVID-19.

Based on the results of a study, this BPOM action led to a distribution license to PT Indofarma Tbk; and production now has commenced with plans for distribution of over 4 million units per month. This fascinating and unfolding situation is the result of the dynamic SOE minister driving state enterprises to solve the COVID-19 crisis as the BPOM still takes the position that the treatment is accepted but on an off-label basis.

But BPOM has declared formally that ivermectin is now authorized as a therapy for COVID-19.

Post a Comment
Market Buzz